TransMedics Group, Inc.
No SEC Form 4 filings for $TMDX in the last 30 days.
See all $TMDX insider activity →TransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.
TransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.
TransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tmdx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy fo
Over the past 7 days, alphai's AI scored 5 news stories mentioning TMDX (TransMedics Group, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 1 bearish.
Recent TMDX coverage spans financial news, earnings and insider activity.
Earnings quality concern (sharp adjusted net income decline) is the immediate driver, despite raised 2026 sales guidance and continued reinvestment.
Guidance raise plus strong Q2 revenue growth supports a bullish near-term re-rating, but margin and operating expense pressure may cap upside.
Guidance raise plus record revenue/service growth is likely supportive, but operating income and margins declined on higher planned investment and cost mix.
Inducement equity grants increase future share issuance potential but are typically not a near-term fundamental catalyst.
Routine employee inducement equity grant with defined strike price and vesting schedule; likely limited incremental impact beyond minor dilution/overhang optics.
alphai scores every news story that mentions TMDX with an AI model for sentiment and relevance, and aggregates insider trades from TransMedics Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.
4 min readTransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.
6 min readTransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tmdx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy fo
4 min readTransMedics (Nasdaq: TMDX) said it granted inducement equity awards on July 29, 2026 to nine new employees under Nasdaq Rule 5635(c)(4). It issued non-qualified stock options for 18,762 shares (10-year term, $78.00 exercise price) and 12,414 restricted stock units. Options vest 25% after one year, then monthly over three years; RSUs vest 25% each of four anniversaries.
2 min readTransMedics Group, Inc. (Nasdaq: TMDX) said it granted non-qualified stock options for 18,762 shares and 12,414 restricted stock units to nine employees on July 29, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4). Options exercise price was $78.00, the July 29 closing price, with 10-year terms.
2 min readTheFly reported July 6 that Evercore ISI cut its TransMedics Group (TMDX) price target to $90 from $100 while keeping an Outperform rating, citing generally stable procedure volumes and capital spending trends. On the same day, TMDX said it will invest in PAD Aviation to expand its Organ Care System OCS program into Europe, aiming to improve organ access and transplant logistics.
4 min readThe article says SoFi (SOFI) shares are down 34% YTD after a short-seller report and weaker forward guidance; SoFi reports Q1 revenue up 43% to $1.1B, adjusted EPS $0.12, and 14.7M users. Robinhood (HOOD) Q1 revenue $1.07B (+15%) but crypto revenue $134M (-47%). TransMedics (TMDX) Q1 revenue $173.9M (+21%) with margin 7.6% and adjusted EPS $0.30.
7 min readGunderson Thomas J. sold 9,624 shares of TransMedics Group, Inc. (TMDX) at $75.06 ($0.72M total) on 2026-06-15.
1 min readTransMedics (TMDX) shares fell as investors questioned the company’s margins, spending, and execution, according to the article. It argues that TransMedics’ Organ Care System, its aviation network, and the National OCS Program could strengthen its position in transplant infrastructure, which may affect investor views on the company’s longer-term growth prospects.
7 min readTransMedics Group, Inc. director Edward M. Basile received an equity grant of 2,922 restricted stock units (RSUs) at no cash cost. This grant increased his direct holdings to 5,788 shares of the company's common stock. The transaction, reported in a Form 4 SEC filing, represents a form of equity compensation rather than a cash purchase or open-market transaction.
2 min read
